Multiple stocks hit the daily limit! The innovative drug sector defies the trend and strengthens, with JinYao Pharmaceutical hitting the limit-up for five consecutive days.

(Source: Caixin)

On the news front, Eli Lilly announced on Wednesday local time that the U.S. Food and Drug Administration (FDA) has approved its GLP-1 oral drug for market launch. In addition, the 37th International Alzheimer’s Disease Association Global Conference will be held in Lyon, France, from April 14-16, 2026.

On April 2, the innovative drug sector saw volatility and then surged strongly. Tianjin Pharmaceutical (600488.SH) hit five consecutive limit-ups. Peking University Health (000788.SZ) and Yibai Pharmaceutical (rights defense) (600594.SH) hit two consecutive limit-ups. Chongyao Holding (000950.SZ), among others, hit the daily limit. Kangzhi Pharmaceutical (300086.SZ), Xin Ganjiang (920367.BJ), and Northland (920047.BJ) rose by more than 10%. Yu Heng Pharmaceutical (002437.SZ), Huisheng Biotech (300871.SZ), Deyuan Pharmaceutical (920735.BJ), Changshan Pharmaceutical (300255.SZ), and Jinbo Biotech (920982.BJ) followed suit with gains.

On the news front, Eli Lilly announced on Wednesday local time that the U.S. Food and Drug Administration (FDA) has approved its GLP-1 oral drug for market launch. In addition, the 37th International Alzheimer’s Disease Association Global Conference will be held in Lyon, France, from April 14-16, 2026.

In addition, the annual meeting of the American Association for Cancer Research will be held from April 17-22, 2026. This year, more than 100 Chinese pharmaceutical companies will appear at AACR, bringing nearly 400 research results, covering multiple current popular targets and frontier technologies.

Guosheng Securities said that in the 2026 government work report, biopharmaceuticals were listed as an emerging pillar industry for the first time. For the pharmaceutical sector, this means that the policy’s positioning for biopharmaceuticals is being upgraded further from “cultivating emerging tracks” to “an important direction for economic growth and industrial upgrading,” in which innovative drugs—being the most core, high-value-added link in the biopharmaceutical industry—have especially clear beneficiary directions.

In addition, the number of innovative drugs under development in China is also ranked No. 1 globally. According to Guosheng Securities’ statistics, as of December 31, 2025, there are 14,088 innovative drugs worldwide that are under research and in an active R&D status, and the number of original drugs by Chinese companies is 4,751 (accounting for 33.7%), exceeding the U.S. (4,019, 28.5%), ranking first. Since 2020, the number of innovative drugs newly entering clinical trials in China has grown rapidly. In 2025, 827 original innovative drugs entered clinical trials for the first time, accounting for 47.4% of the global share.

CMB International pointed out that the positioning of the biopharmaceutical industry has been elevated to an emerging pillar industry, indicating that the policy dividend for the whole value chain will continue to be released. Breakthroughs in AI drug development technology and the surge in Chinese innovative drug outbound BD are creating a dual resonance, and the industry’s fundamentals are expected to accelerate toward improvement. At present, domestic innovative drug outbound cooperation has evolved from single-pipeline licensing to platform-level cooperation, and multinational pharmaceutical companies’ recognition of China’s pharmaceutical R&D strength is increasing systematically.

CCID International stated that under the combined effects of multiple factors—such as policy regulation, industry consolidation, scale effects, and digital upgrades—China’s pharmaceutical distribution industry’s competitive structure has been continuously optimized and reshaped into a “5+N” competitive pattern. However, there is still a certain gap compared with mature markets in terms of industry concentration. Driven by policy guidance, technology empowerment, and deep resonance with market demand, the industry’s intelligent and digital transformation of pharmaceutical distribution is accelerating across the board. As technologies such as the Internet of Things and AI continue to be implemented to enable and empower, high-quality industry resources are expected to gather toward leading enterprises, achieving a major leap from growth driven by scale to growth driven by value.

Endless news and precise analysis—everything on Sina Finance APP